Shanxi Medical University
15
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
0.0%
0 terminated/withdrawn out of 15 trials
100.0%
+13.5% vs industry average
47%
7 trials in Phase 3/4
50%
2 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Study on Gamma Sensory Flicker for Insomnia
Role: collaborator
Prevalence and Risk Indicators of Peri-implant Diseases in China
Role: collaborator
The Influence of Internet + Combined Family Empowerment Management Mode on Treatment Compliance of PATIENTS With CKD
Role: lead
Construction of Theoretical Model of Medical Treatment Behavior of Patients With Chronic Kidney Disease
Role: lead
Immunogenicity of Hepatitis B Vaccination Among Drug Users
Role: lead
Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
Role: lead
The Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students
Role: lead
Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
Role: collaborator
Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population
Role: lead
Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
Role: lead
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Role: collaborator
Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected Patients
Role: lead
Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
Role: collaborator
The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment
Role: lead
Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research
Role: lead
All 15 trials loaded